J. Martinez

发表

A haemagglutination test for rapid detection of antibodies to SARS-CoV-2

P. Klenerman, J. Knight, N. Gupta, 2020, Nature Communications.

A blood atlas of COVID-19 defines hallmarks of disease severity and specificity

Calliope A. Dendrou, I. Pavord, J. Todd, 2021, Cell.

Performance characteristics of five immunoassays for SARS-CoV-2: a head-to-head benchmark comparison

G. Rodger, C. Groves, D. Stuart, 2020, The Lancet Infectious Diseases.

Antibody testing for COVID-19: A report from the National COVID Scientific Advisory Panel

Andrew Pollard, James Whitehouse, A Sarah Walker, 2020, Wellcome open research.

A Newcastle disease virus-vector expressing a prefusion-stabilized spike protein of SARS-CoV-2 induces protective immune responses against prototype virus and variants of concern in mice and hamsters

A. García-Sastre, P. Palese, I. González-Domínguez, 2021, bioRxiv.

Trivalent NDV-HXP-S Vaccine Protects against Phylogenetically Distant SARS-CoV-2 Variants of Concern in Mice

A. García-Sastre, P. Palese, I. González-Domínguez, 2022, Microbiology spectrum.

Trivalent NDV-HXP-S vaccine protects against phylogenetically distant SARS-CoV-2 variants of concern in mice

A. García-Sastre, P. Palese, I. González-Domínguez, 2022, bioRxiv.

Constructing custom-made radiotranscriptomic signatures of vascular inflammation from routine CT angiograms: a prospective outcomes validation study in COVID-19

Calliope A. Dendrou, I. Pavord, G. Rodger, 2022, The Lancet Digital Health.

An inactivated NDV-HXP-S COVID-19 vaccine elicits a higher proportion of neutralizing antibodies in humans than mRNA vaccination

J. Wrammert, D. Sather, P. Pitisuttithum, 2023, Science Translational Medicine.

Safety and immunogenicity of an egg-based inactivated Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Interim results of a randomized, placebo-controlled, phase 1/2 trial in Vietnam

M. Lal, J. McLellan, A. García-Sastre, 2022, Vaccine.

Neutrophils and emergency granulopoiesis drive immune suppression and an extreme response endotype during sepsis

J. Todd, A. Mentzer, I. Udalova, 2023, Nature Immunology.

The inactivated NDV-HXP-S COVID-19 vaccine induces a significantly higher ratio 1 of neutralizing to non-neutralizing antibodies in humans as compared to mRNA 2 vaccines 3

J. Wrammert, D. Sather, P. Pitisuttithum, 2022 .

The inactivated NDV-HXP-S COVID-19 vaccine induces a significantly higher ratio 1 of neutralizing to non-neutralizing antibodies in humans as compared to mRNA 2 vaccines 3

J. Wrammert, D. Sather, P. Pitisuttithum, 2022 .

The inactivated NDV-HXP-S COVID-19 vaccine induces a significantly higher ratio 1 of neutralizing to non-neutralizing antibodies in humans as compared to mRNA 2 vaccines 3

J. Wrammert, D. Sather, P. Pitisuttithum, 2022 .

The inactivated NDV-HXP-S COVID-19 vaccine induces a significantly higher ratio 1 of neutralizing to non-neutralizing antibodies in humans as compared to mRNA 2 vaccines 3

J. Wrammert, D. Sather, P. Pitisuttithum, 2022 .

The inactivated NDV-HXP-S COVID-19 vaccine induces a significantly higher ratio 1 of neutralizing to non-neutralizing antibodies in humans as compared to mRNA 2 vaccines 3

J. Wrammert, D. Sather, P. Pitisuttithum, 2022 .

The inactivated NDV-HXP-S COVID-19 vaccine induces a significantly higher ratio 1 of neutralizing to non-neutralizing antibodies in humans as compared to mRNA 2 vaccines 3

J. Wrammert, D. Sather, P. Pitisuttithum, 2022 .

The inactivated NDV-HXP-S COVID-19 vaccine induces a significantly higher ratio 1 of neutralizing to non-neutralizing antibodies in humans as compared to mRNA 2 vaccines 3

J. Wrammert, D. Sather, P. Pitisuttithum, 2022 .

The inactivated NDV-HXP-S COVID-19 vaccine induces a significantly higher ratio 1 of neutralizing to non-neutralizing antibodies in humans as compared to mRNA 2 vaccines 3

J. Wrammert, D. Sather, P. Pitisuttithum, 2022 .

589. Oral Tablet Vaccination Induces Heightened Cross-Reactive CD8 T Cell Responses to SARS-COV-2 in Humans

E. Dora, Shaily J. Garg, S. Tucker, 2021, Open Forum Infectious Diseases.

Intranasal SARS-CoV-2 Omicron variant vaccines elicit humoral and cellular mucosal immunity in female mice

P. Palese, I. González-Domínguez, F. Krammer, 2024, EBioMedicine.